WO1992009281A3 - Utilisation de paroxetine pour le traitement de la demence senile, la boulimie, la migraine ou l'anorexie - Google Patents

Utilisation de paroxetine pour le traitement de la demence senile, la boulimie, la migraine ou l'anorexie Download PDF

Info

Publication number
WO1992009281A3
WO1992009281A3 PCT/GB1991/002062 GB9102062W WO9209281A3 WO 1992009281 A3 WO1992009281 A3 WO 1992009281A3 GB 9102062 W GB9102062 W GB 9102062W WO 9209281 A3 WO9209281 A3 WO 9209281A3
Authority
WO
WIPO (PCT)
Prior art keywords
paroxetine
treatment
bulimia
anorexia
migraine
Prior art date
Application number
PCT/GB1991/002062
Other languages
English (en)
Other versions
WO1992009281A2 (fr
Inventor
Anthony Michael Johnson
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909025594A external-priority patent/GB9025594D0/en
Priority claimed from GB909025595A external-priority patent/GB9025595D0/en
Priority claimed from GB909025592A external-priority patent/GB9025592D0/en
Priority claimed from GB909025593A external-priority patent/GB9025593D0/en
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Priority to AU89153/91A priority Critical patent/AU658155B2/en
Priority to JP4500444A priority patent/JPH06502854A/ja
Priority to US08/064,088 priority patent/US5371092A/en
Priority to KR1019930701533A priority patent/KR930702000A/ko
Publication of WO1992009281A2 publication Critical patent/WO1992009281A2/fr
Publication of WO1992009281A3 publication Critical patent/WO1992009281A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

On décrit l'utilisation de la paroxetine ou d'un sel pharmaceutiquement acceptable de celle-ci pour la fabrication d'un médicament destiné au traitement de la démence sénile.
PCT/GB1991/002062 1990-11-24 1991-11-21 Utilisation de paroxetine pour le traitement de la demence senile, la boulimie, la migraine ou l'anorexie WO1992009281A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU89153/91A AU658155B2 (en) 1990-11-24 1991-11-21 Use of paroxetine for the treatment of senile dementia, or anorexia
JP4500444A JPH06502854A (ja) 1990-11-24 1991-11-21 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
US08/064,088 US5371092A (en) 1990-11-24 1991-11-21 Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
KR1019930701533A KR930702000A (ko) 1990-11-24 1991-11-21 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB909025594A GB9025594D0 (en) 1990-11-24 1990-11-24 Treatment method
GB909025595A GB9025595D0 (en) 1990-11-24 1990-11-24 Treatment method
GB909025592A GB9025592D0 (en) 1990-11-24 1990-11-24 Treatment method
GB9025595.1 1990-11-24
GB9025593.6 1990-11-24
GB9025594.4 1990-11-24
GB909025593A GB9025593D0 (en) 1990-11-24 1990-11-24 Treatment method
GB9025592.8 1990-11-24

Publications (2)

Publication Number Publication Date
WO1992009281A2 WO1992009281A2 (fr) 1992-06-11
WO1992009281A3 true WO1992009281A3 (fr) 1992-10-01

Family

ID=27450585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/002062 WO1992009281A2 (fr) 1990-11-24 1991-11-21 Utilisation de paroxetine pour le traitement de la demence senile, la boulimie, la migraine ou l'anorexie

Country Status (8)

Country Link
US (1) US5371092A (fr)
EP (1) EP0558679A1 (fr)
JP (1) JPH06502854A (fr)
KR (1) KR930702000A (fr)
AU (1) AU658155B2 (fr)
CA (1) CA2096853A1 (fr)
IE (1) IE914069A1 (fr)
WO (1) WO1992009281A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
EP0994872B9 (fr) * 1997-06-10 2001-12-05 Synthon B.V. Composes 4-phenylpiperidine
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
AU739261B2 (en) 1997-07-01 2001-10-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
US6300343B1 (en) 1998-06-16 2001-10-09 Smithkline Beecham Corporation Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (fr) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Nouvelle preparation
GB9916392D0 (en) * 1999-07-13 1999-09-15 Smithkline Beecham Plc Novel process
GB9920147D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel process
GB9923540D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9923539D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
US6906206B2 (en) * 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
CA2361882A1 (fr) * 2001-10-19 2003-04-19 Bernard Charles Sherman Liquide pour administration orale contenant de la paroxetine
WO2003057151A2 (fr) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. Formulation pharmaceutique stable d'hydrochlorure de paroxetine anhydre et procede de preparation
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US9138430B2 (en) 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
EP2595621A1 (fr) * 2010-07-20 2013-05-29 Phytopharm PLC Traitement de troubles induits par la l-dopa, un agoniste de dopamine et/ou un activateur de dopamine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007196A (en) * 1973-01-30 1977-02-08 A/S Ferrosan 4-Phenylpiperidine compounds
EP0188081A2 (fr) * 1984-12-04 1986-07-23 Novo Nordisk A/S Utilisation de paroxétine pour l'obtention d'un medicament pour le traitement del'obèsitè
EP0226574A1 (fr) * 1984-07-20 1987-07-01 Bosch Gmbh Robert Detecteur a magnetoresistance pour la production de signaux electriques.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007196A (en) * 1973-01-30 1977-02-08 A/S Ferrosan 4-Phenylpiperidine compounds
EP0226574A1 (fr) * 1984-07-20 1987-07-01 Bosch Gmbh Robert Detecteur a magnetoresistance pour la production de signaux electriques.
EP0188081A2 (fr) * 1984-12-04 1986-07-23 Novo Nordisk A/S Utilisation de paroxétine pour l'obtention d'un medicament pour le traitement del'obèsitè

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Acta Psychiatrica Scandinavica, vol. 80, suppl. 350, 1989, S.A. MONTGOMERY: "New antidepressants and 5-HT uptake inhibitors", pages 107-116, see page 108, column 2, paragraph 2; page 114, column 1, last paragraph *
American Journal of Psychiatry, vol. 146, June 1989, E. HOLLANDER et al.: "Treatment of body-dysmorphic disorder with serotonin reuptake blockers", pages 768-770, see the whole document *
Annals of the New York Academy of Sciences, vol. 600, October 1990, (New York, US), A.J. CROSS: "Serotonin in Alzheimer-type dementia and other dementing illnesses", pages 405-417, see page 406, table 1; pages 412-413 *
Current Therapeutic Research, vol. 25, no. 2, February 1979, E. SYVÄLAHTI et al.: "Migraine headache and blood serotonin levels after administration of zimelidine, a selective inhibitor of serotonin uptake", pages 299-310, see the whole document *
European Journal of Pharmacology, vol. 183, no. 5, July 1990, M.D. COTRIM et al.: "Migraine and serotonin uptake, 3Hdelta-paroxetine and 3H-imipramine binding", page 1917, see the whole document *
International Journal of Geriatric Psychiatry, vol. 3, 1988, John Wiley & Sons, Ltd, J. BALLDIN et al.: "Relationship between DST and the serotonergic system. Results from treatments with two 5-HT reuptake blockers in dementia disorders", pages 17-26, see page 18, column 2, lines 15-39; page 19, column 2, lines 25-38 *
International Journal of Obesity, vol. 11, suppl. 3, December 1987, C.P.L. FREEMAN et al.: "Fluoxetine as a treatment for bulimia nervosa", pages 171-177, see the whole document *
Progress in Drug Research, vol. 35, 1990, (Basel, CH), R.W. FULLER: "Drugs affecting serotonin neurons", pages 85-108, see page 87, paragraph 3 - page 88; page 89, paragraph 9; page 99, paragraph 2 *

Also Published As

Publication number Publication date
JPH06502854A (ja) 1994-03-31
EP0558679A1 (fr) 1993-09-08
AU8915391A (en) 1992-06-25
IE914069A1 (en) 1992-06-03
US5371092A (en) 1994-12-06
WO1992009281A2 (fr) 1992-06-11
CA2096853A1 (fr) 1992-05-25
AU658155B2 (en) 1995-04-06
KR930702000A (ko) 1993-09-08

Similar Documents

Publication Publication Date Title
WO1992009281A3 (fr) Utilisation de paroxetine pour le traitement de la demence senile, la boulimie, la migraine ou l'anorexie
CA2186260A1 (fr) Composition contenant de la morphine, du polypyrrolidone et un polyalyleneoxyde
CA2086974A1 (fr) R(+)-terazosine
CA2180535A1 (fr) Procede de traitement du psoriasis par omeprazole ou autres composes apparentes
HUT61196A (en) Process for producing pharmaceutical composition which may be dropped in the eye
MY112102A (en) Therapeutic heterocycles.
AU5802196A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers
AP8800106A0 (en) Substituted tetrarins chromans & related compounds in the treatment of asthma,arthritis etc.
HUT50092A (en) Process for producing 1,3-glycols from epoxides
CA2006267A1 (fr) Methode de traitement de l'herpes
EP0485218A3 (en) Process for preparing (1'r,3s)-3-(1'-hydroxy-ethyl)-azetidin-2-one and derivatives thereof
WO1993000094A3 (fr) Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine
TW362096B (en) Novel piperidine derivatives and the process for preparing the same
HUT56492A (en) Process for producing 3-arylcarbonyl-1-aminoalkyl-1h-indole derivatives and pharamceutical compositions comprising such compounds, against glaucoma
AU8786491A (en) Hydrazone derivatives, processes for production thereof, and uses thereof
EP0445589A3 (en) Process for the preparation of 1,4-alkylenediamines
EP0551062A3 (en) Polymer composition which withstands sterilization carried out by irradiation, and a method for the production thereof
CA2219308A1 (fr) Nouveau procede de preparation de monohydrate d'hydrochlorure de ropivacaine
HU9200354D0 (en) Process for the production of 2-ethyl-4-/2'/-1h-1,2,3,4-tetrazole-5-yl/-biphenyl-4-yl/-metoxi/-kinoline-hydrocloride
EP0440406A3 (en) Process for producing titanium dioxide
ZA916638B (en) Phosphonopyrrolidine-and piperidine-containing pseudopeptides of the statin type,a process for their preparation and their use as medicaments against retroviruses
ZA924595B (en) Process for the production of 1-(n)-acetyl-3,5,7-trinitrocyclotetramethylenetetramine
EP0038003A3 (fr) Pyrrolylpipéridines comme antidépresseurs
EP0475272A3 (en) Process for the preparation of 2,3,5-trimethyl-p-benzoquinone
AU8931591A (en) Pyridyl-pyrimidin-derivates, process for producing the same, agents containing the same and their use as fungicides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1992902522

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2096853

Country of ref document: CA

Ref document number: 08064088

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1992902522

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992902522

Country of ref document: EP